Related references
Note: Only part of the references are listed.Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats
Rahul Vats et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2012)
Effect of Grapefruit Juice and Ritonavir on Pharmacokinetics of Lopinavir in Wistar Rats
P. R. Ravi et al.
PHYTOTHERAPY RESEARCH (2012)
Anti-platelet therapy: phosphodiesterase inhibitors
Paolo Gresele et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Novel agents for anti-platelet therapy
Xuebin Ji et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Sex differences in pharmacokinetics of cilostazol in rats
Naoki Kamada et al.
XENOBIOTICA (2011)
Enhancement of Oral Bioavailability of Cilostazol by Forming its Inclusion Complexes
Samir G. Patel et al.
AAPS PHARMSCITECH (2009)
Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study
Kanthi Kiran V. S. Varanasi et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: Relevance of first- pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism
Yvonne Y. Lau et al.
DRUG METABOLISM AND DISPOSITION (2006)
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin
JH Hochman et al.
PHARMACEUTICAL RESEARCH (2004)
Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine
K Takara et al.
DRUG METABOLISM AND DISPOSITION (2003)
Limited influence of P-glycoprotein on small-intestinal absorption of cilostazol, a high absorptive permeability drug
H Toyobuku et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Clinical pharmacokinetics of atorvastatin
H Lennernas
CLINICAL PHARMACOKINETICS (2003)
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin
TA Clarke et al.
DRUG METABOLISM AND DISPOSITION (2003)
Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization
T Prueksaritanont et al.
DRUG METABOLISM AND DISPOSITION (2002)
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors
D Williams et al.
CLINICAL PHARMACOKINETICS (2002)
The pharmacology of cilostazol
K Schror
DIABETES OBESITY & METABOLISM (2002)
Pharmacokinetic interactions of statins
RF Reinoso et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2001)
Peripheral arterial disease detection, awareness, and treatment in primary care
AT Hirsch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Drug therapy - Medical treatment of peripheral arterial disease and claudication.
WR Hiatt
NEW ENGLAND JOURNAL OF MEDICINE (2001)
In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms
R Abbas et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2000)
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion
RA Boyd et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
